TABLE 1.
Participant measures by Aβ positivity
| Aβ− | Aβ+ | P | |
|---|---|---|---|
| n (%) | 102 (64.1) | 57 (35.8) | |
| Age, Exam 1, M (SD) | 54.3 (6.3) | 58.4 (6.5) | <.001* |
| Age, Exam 6, M (SD) | 70.1 (6.2) | 74.5 (6.5) | <.001* |
| Sex (M/F) | 47/55 | 24/33 | .629 |
| Race (White/AA) | 48/54 | 32/25 | .272 |
| Years of education, M (SD) | 15.0 (2.6) | 15.1 (2.9) | .857 |
| aCognitive status, n (%) | <.001* | ||
| Normal | 79 (78.2) | 27 (48.2) | |
| MCI | 19 (18.8) | 23 (41.1) | |
| Dementia | 1 (1.0) | 5 (8.9) | |
| APOE-ε4, (+/−/missing) | 26/75/1 | 27/25/5 | <.001* |
| %ASCVD, M (SD) | 6.59 (5.7) | 8.01 (6.4) | .152 |
| b% FSRP, M (SD) | 1.69 (1.6) | 2.69 (2.7) | .004* |
| CAIDE, M (SD) | 6.48 (2.2) | 7.65 (2.2) | .002* |
| SBP, M (SD) | 127.0 (21.7) | 126.9 (18.6) | .965 |
| DBP, M (SD) | 73.9 (10.4) | 73.5 (10.1) | .828 |
| cCASI Exam 5, M (SD) | 92.3 (5.9) | 92.1 (5.3) | .865 |
| dCASI Exam 6, M (SD) | 93.6 (4.5) | 90.3 (8.4) | .002* |
| eCASI change (5 to 6), M (SD) | 1.4 (5.0) | −1.8 (6.8) | .001* |
| PiB SUVR, M (SD) | 1.11 (0.05) | 1.71 (0.27) | <.001* |
| fWMH vol. (% ICV), median (IQR) | 0.19 (0.10, 0.42) | 0.33 (0.14, 0.72) | .025* |
| dCort. thick., mm, M (SD) | 2.69 (0.12) | 2.65 (0.13) | .037* |
Abbreviations: Aβ, β-amyloid; ASCVD, atherosclerotic cardiovascular disease risk estimate from the pooled cohort equation; FSRP, Framingham stroke risk profile; CAIDE, cardiovascular risk factors, aging and incidence of dementia risk score; SBP, systolic blood pressure; DBP, diastolic blood pressure; CASI, Cognitive Abilities Screening Instrument; PiB SUVR, Pittsburgh compound B Standardized Uptake Value Ratio; Cort. thick., cortical thickness; WMH vol., white matter hyperintensity volume; ICV, intracranial volume.
Statistically significant at P < .05.
Note: 5 participants (3 Aβ−, 2 Aβ+) did not have cognitive status available
Aβ− n = 99; Aβ+ n = 55.
Aβ− n = 101; Aβ+ n = 57.
Aβ− n = 99; Aβ+ n = 57.
Aβ− n = 102; Aβ+ n = 56.
Aβ− n = 99; Aβ+ n = 56.
Aβ− n = 101; Aβ+ n = 56.